SCHEDULE: Matrix Capital Reduces Zentalis Stake, Director Resigns

Matrix Capital Management Company, LP reduced its stake in Zentalis Pharmaceuticals, Inc. to 9.98% through a share repurchase, coinciding with a director's resignation.

Summary

• Matrix Capital Management Company, LP and David E. Goel reported a change in their beneficial ownership of Zentalis Pharmaceuticals, Inc. common stock.
• Karan Takhar, a Senior Managing Director of Matrix Capital's Investment Manager, resigned from Zentalis's board of directors on December 15, 2025.
• The Matrix Fund sold 7,500,000 shares of Zentalis Common Stock back to the Issuer at a price of $1.33 per share in a transaction that closed on December 15, 2025.
• Following the repurchase, Matrix Capital and David E. Goel beneficially own 6,459,973 shares, representing 9.98% of the outstanding Common Stock.
• The percentage is calculated based on 64,750,779 shares outstanding after subtracting the repurchased shares from the 72,250,779 shares outstanding as of November 1, 2025.

Sentiment

Score: 3

Explanation: The filing indicates a significant reduction in stake by a major institutional investor and the resignation of their representative from the board. While the company repurchased shares, the investor's exit from a significant position and board seat typically signals a negative sentiment or strategic divergence, outweighing the potential positive of a share repurchase.

Positives

• Zentalis Pharmaceuticals, Inc. repurchased 7,500,000 shares of its common stock, which can reduce the total share count and potentially increase earnings per share for remaining shareholders.

Negatives

• A significant institutional investor, Matrix Capital Management Company, LP, reduced its stake in Zentalis Pharmaceuticals, Inc. to 9.98%.
• Karan Takhar, a Senior Managing Director of Matrix Capital's Investment Manager, resigned from Zentalis's board of directors, potentially signaling a loss of confidence or strategic divergence from a major investor.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investor reducing its stake in a pharmaceutical company. In the biotech/pharma industry, institutional investor confidence and board representation are often closely watched indicators. A reduction in stake and board resignation by a major investor could signal a re-evaluation of the company's prospects or a strategic shift by the investor, potentially impacting market perception.

Comparison to Industry Standards

• Institutional investors frequently adjust their positions in biotech companies based on clinical trial results, regulatory milestones, and strategic direction. A reduction in stake by a prominent fund like Matrix Capital could be compared to similar moves by other large healthcare-focused funds in companies facing pipeline challenges or strategic pivots.
• Share repurchases are common across industries, often used to return capital to shareholders or reduce dilution. The specific price of $1.33 per share for the repurchase would need to be compared to Zentalis's market price around December 15, 2025, and to repurchase prices of comparable biotech firms to assess its attractiveness.
• Board resignations, especially from representatives of significant shareholders, are not uncommon but can sometimes precede or follow strategic disagreements or a change in the investor's long-term commitment.

Management Changes

Related Party Transactions

• The Issuer repurchased 7,500,000 shares of Common Stock from the Matrix Fund at $1.33 per share. This transaction involves a significant shareholder and former board representative.

Stakeholder Impact

• Shareholders: Remaining shareholders might see a slight increase in per-share metrics due to the reduced share count. However, the departure of a major institutional investor and board member could raise concerns about future strategic direction or investor confidence, potentially impacting share price negatively.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

The departure of a significant institutional investor like Matrix Capital, coupled with their representative's resignation from the board, often signals a loss of confidence or a strategic divergence. While the share repurchase reduces the outstanding share count, the underlying reason for the investor's exit could indicate fundamental issues or a lack of future growth catalysts, making the stock a less attractive investment. This move by a sophisticated investor suggests a negative outlook.

Keywords

Zentalis Pharmaceuticals, Matrix Capital Management, Schedule 13D, share repurchase, beneficial ownership, board resignation, institutional investor, common stock